193 Spam-Free Article(s) Found
Sort:
Date
Filter:
All
Symbol Name Last Close Mkt Cap DailyStocks'
Rating
Our DailyStocks’ Rating System is a proprietary algorithm that combines the vote of the investor community and legendary trader Richard Dennis’ Turtle Trader System and the System Rules of the Turtle Traders Each day, we generate Buy, Sell, Uptrend or Downtrend signals for 3000 Stocks in the U.S. Markets.
Vote Now!
Thursday’s Close
NVO Novo Nordisk A/S $47.64 $114.84B N/A
Article Searches
5 Biotech and Pharma Stocks with FDA Catalysts this December http://www.zacks.com/stock/news/284530/5-biotech-and-pharma-stocks-with-fda-catalysts-this-december?cid=CS-ZC-FT-284530 Nov 30, 2017 - As we enter the last month of the year, here is a look at some pharma and biotech companies including Amgen (AMGN) that await a decision from the FDA for label expansions or new drugs.
2 Large-Cap Drug Stocks Missing Out on Industry Rally in '17 http://www.zacks.com/stock/news/284280/2-large-cap-drug-stocks-missing-out-on-industry-rally-in-17?cid=CS-ZC-FT-284280 Nov 28, 2017 - Most drug companies with a larger market cap have seen their share price rising this year. However, a couple of large-cap pharma companies have witnessed a downside this year.
Novo Nordisk (NVO) Investor Presentation - Slideshow https://seekingalpha.com/article/4127163-novo-nordisk-nvo-investor-presentation-slideshow?source=feed_sector_healthcare Nov 22, 2017 - The following slide deck was published by Novo Nordisk A/S in conjunction with this event.
Novo Nordisk (NVO) Investor Presentation - Slideshow https://seekingalpha.com/article/4127164-novo-nordisk-nvo-investor-presentation-slideshow?source=feed_sector_healthcare Nov 22, 2017 - The following slide deck was published by Novo Nordisk A/S in conjunction with this event.
MannKind CEO Michael Castagna on What's Ahead for the Biotech https://www.fool.com/investing/2017/11/21/mannkind-ceo-michael-castagna-on-whats-ahead-for-t.aspx?source=iedfolrf0000001 Nov 21, 2017 - A conversation with MannKind's CEO about the biotech's future with Afrezza, payers, partners, and pipeline candidates.
An Interview With MannKind CEO Michael Castagna https://www.fool.com/investing/2017/11/19/an-interview-with-mannkind-ceo-michael-castagna.aspx?source=iedfolrf0000001 Nov 19, 2017 - The biotech's CEO talks about how MannKind now has the wind at its back after his first six months at the helm.
Roche's (RHHBY) Hemophilia A Drug Receives FDA Approval http://www.zacks.com/stock/news/283257/roches-rhhby-hemophilia-a-drug-receives-fda-approval?cid=CS-ZC-FT-283257 Nov 17, 2017 - Roche (RHHBY) hematology portfolio got a boost when the FDA approved Hemlibra (emicizumab-kxwh) for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adults and children with haemophilia A with factor VIII inhibitors.
The Zacks Analyst Blog Highlights: TOTAL S.A., Humana, Novo Nordisk, Target and Xcel http://www.zacks.com/stock/news/283255/the-zacks-analyst-blog-highlights-total-sa-humana-novo-nordisk-target-and-xcel?cid=CS-ZC-FT-283255 Nov 17, 2017 - The Zacks Analyst Blog Highlights: TOTAL S.A., Humana, Novo Nordisk, Target and Xcel
Top Analyst Reports for TOTAL S.A., Humana & Novo Nordisk http://www.zacks.com/research-daily/137429/top-analyst-reports-for-total-sa-humana-novo-nordisk?cid=CS-ZC-FT-137429 Nov 16, 2017 - Top Analyst Reports for TOTAL S.A., Humana & Novo Nordisk
J&J Presents Positive New Data for Diabetes Drug Invokana http://www.zacks.com/stock/news/283004/jj-presents-positive-new-data-for-diabetes-drug-invokana?cid=CS-ZC-FT-283004 Nov 15, 2017 - Johnson & Johnson (JNJ) puts forth positive data from CANVAS study on its type II diabetes drug, Invokana, showing better renal outcomes.

Pages: 1...1011121314151617181920

<<<Page 15>